Literature DB >> 6992910

The effect of naftidrofuryl (Praxilene) on intermittent claudication.

K J Waters, A D Craxford, J Chamberlain.   

Abstract

In a randomized double-blind controlled trial the effect of naftidrofuryl (Praxilene) 200 mg t.d.s., taken for 6 months, was compared with placebo in intermittent claudication. Whilst there was a significant subjective improvement regardless of age or treatment, patients over 60 on naftidrofuryl experienced a more rapid symptomatic relief than other patients. At six months this age group showed a significant improvement over the placebo group. There was no significnat objective evidence of improvement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992910     DOI: 10.1002/bjs.1800670516

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

Review 1.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

2. 

Authors:  C Diehm; H Heidrich; F Spengel; K L Schulte; W Theiss
Journal:  Internist (Berl)       Date:  2000-11       Impact factor: 0.743

Review 3.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

4.  Treating claudication in five words.

Authors:  E Housley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-28

Review 5.  Non-surgical management of peripheral vascular disease: a review.

Authors:  C A Clyne
Journal:  Br Med J       Date:  1980-09-20

6.  Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Authors:  A Aukland; R A Hurlow; A J George; J Stuart
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.